In a randomized clinical trial, overweight adults who increased their nightly sleep duration by about an hour reduced their daily caloric intake by an average of 270 kcal, which would lead to weight loss over time.
University Hospitals Cleveland Medical Center and UH Rainbow Babies and Children’s Hospital are participating in a Cochlear Americas’-sponsored clinical trial for an implantable hearing device in children 5 to 11 years of age who have been born with hearing loss that may be caused by craniofacial abnormalities. UH was the first site in the nation to kick off the trial.
Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.
UChicago Medicine oncologist Wendy Stock, MD, has been named co-chair of the Leukemia Committee of the Alliance for Clinical Trials in Oncology.
Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.
The National Football League is funding a novel clinical trial by UC San Diego researchers to assess whether cannabis or CBD provide any post-game pain relief caused by athletic injury. Trial participants will be professional rugby players.
Sanjay Goel, MD, MS has been named director of Rutgers Cancer Institute of New Jersey's Phase I/Investigational Therapeutics Program, a multidisciplinary scientific group designed to develop new methods for the treatment of cancer in collaboration with colleagues across the RWJBarnabas Health system.
Kristi Taylor enrolled in a clinical trial at UTHealth Houston that is testing the efficacy and safety of fenebrutinib – a medication that inhibits the activity of certain malignant white blood cells – on the progression of disability in adult participants with primary progressive multiple sclerosis.
An ongoing study just published in The New England Journal of Medicine was pivotal in allowing mixed use of booster COVID-19 shots -- critical as the U.S. experienced the Omicron surge.
In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.
Ten years ago, on Jan. 23, 2012, the brand-new University of Kansas Clinical Research Center opened its doors.
The PFF embraces International Quality of Life Month as an opportunity to shine a spotlight on emerging treatments and supportive resources that can improve quality of life for patients affected by pulmonary fibrosis – a debilitating, often incurable lung disease affecting more than 250,000 Americans.
Researchers are studying whether a drug already approved to treat neurodegenerative diseases can be repurposed to help trauma surgeons determine whether nerves are severed or non-severed in peripheral nerve injuries.
• In an analysis of data from a recent clinical trial, researchers found that removing a race-based adjustment in the estimation of individuals’ kidney function had a small but potentially important impact on the inclusion of participants, with differing effects on Black and non-Black participants. • Removal of the race-based adjustment also influenced inclusion parameters such as participants’ severity of kidney function impairment at baseline as well as their risk of developing cardiovascular- and kidney-related outcomes.
A new study shows that an FDA-approved, pharmaceutical-grade formulation of CBD has an antiviral effect in human lung cells and mice, and shows a significant negative association with COVID infection in human patients.
University of Utah Health scientists are testing a new contraceptive gel for men. Based on preliminary research, the scientists believe the hormonal gel decreases a man’s sperm production––reducing his chances of fathering a child––without decreasing his sex drive.
In a phase 2 clinical trial conducted by Avalo Therapeutics and supported by researchers from Sanford Burnham Prebys, a significantly higher proportion of hospitalized patients with COVID-19 remained alive and free of respiratory failure for 28 days after receiving treatment with a new antibody called CERC-002. Unlike other experimental COVID therapies, CERC-002 does not target the virus itself, instead targeting the immune response associated with the virus to stop the disease from progressing before it becomes fatal.
In a new meta-analysis of randomized, placebo-controlled COVID-19 vaccine trials, researchers compared the rates of adverse events reported by participants who received the vaccines to the rates of adverse events reported by those who received a placebo injection.
Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy—also pioneered at Penn—for solid cancer tumors and offers a promising new strategy in the fight against cancer. Preliminary data from the Phase 1 multi-center clinical trial, which uses a novel, gene-based cancer therapy with CAR-engineered macrophages to target recurrent or metastatic HER2-positive solid tumors, was presented during the recent Society for Immunotherapy of Cancer (SITC) annual meeting.
Oxytocin’s role in regulating and influencing social behavior is well known. Numerous ongoing clinical trials are focusing on the levels of the hormone in the brain but now a Florida State University research team has found evidence that oxytocin receptors outside of the brain may play an important role in shaping social behavior.
the NIH Collaboratory is donning a new name—NIH Pragmatic Trials Collaboratory—that will carry the highly successful program into the future with a continued commitment to transforming clinical research. The program was formerly known as the NIH Health Care Systems Research Collaboratory. Its new moniker reflects the program’s core mission of strengthening the national capacity to implement cost-effective, large-scale research studies conducted within healthcare delivery systems, also known as pragmatic trials.
 (1).png&width=400&height=400)
Prevention of eating disorders (EDs) is of high importance. However, digital programs with human moderation are unlikely to be disseminated widely. The aim of this study was to test whether a chatbot (i.e., computer program simulating human conversation) would significantly reduce ED risk factors (i.e., weight/shape concerns, thin-ideal internalization) in women at high risk for an ED, compared to waitlist control, as well as whether it would significantly reduce overall ED psychopathology, depression, and anxiety and prevent ED onset.
RareCyte Inc., ("RareCyte" or "The Company") a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021.
Wistar announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic therapeutic development company, today announced the topline results of the first in human Phase 2 clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.
Zahn, a professor of pediatrics and the director of the Guerin Family Congenital Heart Program in the Smidt Heart Institute, was the principal investigator for the multicenter clinical trial which led to the FDA's approval today. He says the new device will allow interventional cardiologists to treat more patients.
Generalized pustular psoriasis (GPP) is a rare, life-threatening skin condition for which there are no approved treatments. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus). There is a high unmet need for treatments that can rapidly and completely resolve the signs and symptoms of GPP flares. Flares greatly affect a person’s quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold – up to 25 years before the expected onset of dementia.
An alternative statistical method honed and advanced by Cornell researchers can make clinical trials more reliable and trustworthy while also helping to remedy what has been called a “replicability crisis” in the scientific community.
Ian E. Krop, MD, PhD, has been appointed Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research, and Director of the Yale Cancer Center Clinical Trials Office.
The associate director for the clinical research program at UC Davis Comprehensive Cancer Center embarks on new leadership role in early 2022 as CEO of the International Association for the Study of Lung Cancer
.jpg&width=400&height=400)
Axicabtagene ciloleucel, known by the brand name Yescarta, is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
Results of a 12-month multicenter randomized clinical trial led by Erika Petersen, M.D., a professor of neurosurgery at the University of Arkansas for Medical Sciences (UAMS), were published online Nov. 29 in Diabetes Care, highlighting the benefits of a breakthrough treatment for patients with painful diabetic neuropathy (PDN).
Research Shows Vaccine Has 90 Percent Efficacy at Preventing Infections; Moderate to Severe Disease Occurred Only in Placebo Recipients
.A drug used to treat cardiac failure has shown promising results in treating triple negative breast cancer, according to Houston Methodist researchers who released results this week on a new combined therapy with the potential to improve outcomes for these hard-to-treat breast cancer patients.
The Latest Mental Health Research and Feature News in the Mental Health Channel on Newswise
In a new study in the December 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network researchers examined published randomized control trials supporting FDA approval for treatments for solid tumors from January 2015 through December 2019—and found that for 33 out of 81 studies, it was not clear in the publication why or how patients were being censored (i.e. removed from follow-up before experiencing the outcome of interest).
While the rapid development of effective vaccines has helped combat the COVID-19 pandemic, key communities – especially people who are living with HIV – remain disproportionately impacted, and are at higher risk of severe disease and death. Finding an effective HIV vaccine is critically important, and to that end, the HIV Vaccine Trials Network (HVTN) is launching an expanded Faith Initiative that will help advance the work of finding a cure.
The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.
Researchers at Washington University School of Medicine in St. Louis have shown, in a small clinical trial, that an immunotherapy harnessing pre-activated natural killer cells can help some children and young adults with recurrent AML and few other treatment options.
The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections. It also is the first study to evaluate the efficacy of vaccines – in this case, Moderna mRNA-1273 – against the omicron variant of SARS-CoV-2, the virus that causes COVID-19.
Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual meeting in December.
Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers. The cellular therapy uses a patient’s own immune cells that are reengineered to better seek out and destroy cancer cells. The single infusion treatment is approved for patients who have relapsed after two or more types of therapy but results from the ZUMA-7 clinical trial show lymphoma patients can benefit from receiving the CAR T product axicabtagene ciloleucel (Yescarta) sooner.
Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.
Deciding which medication to prescribe for a new epilepsy diagnosis is an issue without much guidance. The second Standard And New Anti-epileptic Drugs study (SANAD II) compared medications for both focal and generalized epilepsies.
Physicians and researchers presented the latest scientific developments into pulmonary fibrosis and interstitial lung disease at its biennial PFF Summit in November. Registration is still open at PFFSummit.org to view all sessions on-demand through Feb. 20, 2022.
.jpg&width=400&height=400)
Human trials are set to begin for two next-generation COVID-19 vaccines developed by a team of scientists at McMaster University.
St. Jude Children’s Research Hospital phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
